The specter of generic challenges has consistently loomed around copyright’s iconic drug, Viagra, sparking questions about the prospects of connected pharmaceutical holdings. While first periods saw substantial returns, the intellectual property expiration has created the path for less expensive copies, possibly diminishing earnings and creating